Get the Daily Brief
Latest Biotech News
CIRM Commits $100M to Platform Gene‑Therapy Paths for Rare Diseases
California Institute for Regenerative Medicine approved a $100 million RAPID initiative to accelerate platform‑based in vivo genetic therapies for rare diseases. The program will fund scalable...
Wearable Aptamer Patch Clears Human Pilot: Continuous Drug Monitoring Arrives
A wearable electrochemical aptamer‑based patch demonstrated continuous, real‑time drug concentration measurements in healthy human participants in a pilot clinical trial, with findings reported in...
Hologic Wins Expanded FDA Clearance for Aptima HPV: Clinician‑Collected Primary Screening
The US Food and Drug Administration expanded Hologic’s Aptima HPV assay indication to include clinician‑collected primary HPV screening, adding flexibility for cervical cancer screening...
Congress Clears Medicare Path for FDA‑Approved MCED Tests — Coverage Comes in 2029
A federal spending bill approved by Congress includes a provision that will allow Medicare to cover FDA‑approved multi‑cancer early detection (MCED) tests starting in 2029, effectively decoupling...
Biotech IPO rebound: Eikon prices at top, Veradermics upsizes offering
Eikon Therapeutics completed a high-profile IPO, selling shares at the top of its range to raise $381 million and send a signal that well-funded, platform-driven biotechs can still access public...
Pfizer’s Metsera buy shows promise: monthly GLP‑1 posts competitive Phase 2 results
Pfizer disclosed Phase 2 data from the monthly GLP‑1 acquired through its $10 billion Metsera purchase, reporting clinically meaningful weight loss and confirming the drug's potential as a...
Lilly surge... GLP‑1 sales lift results and outlook
Eli Lilly reported results that beat street forecasts, driven by blockbuster performance of its GLP‑1 portfolio. Combined 2025 sales of Lilly’s obesity medicines—Zepbound and Mounjaro—surpassed...
Pediatric PRV reauthorized: lawmakers restore a rare‑disease incentive
Congress reauthorized the Pediatric Priority Review Voucher (PPRV) program through 2029 as part of a short‑term funding package, and industry groups including BIO hailed the move. BIO’s CEO John...
NIH turmoil escalates: Senate report and leadership clashes put research at risk
A Senate HELP hearing and an accompanying report accused the current administration of disrupting NIH research funding, citing terminations and freezes that the report says have imperiled cancer,...
FDA signals tailored oversight: CAR‑T for autoimmune disease gets a cautious green light
The FDA signaled a willingness to adopt a flexible, risk‑proportionate regulatory approach for CAR‑T therapies targeting autoimmune disorders, indicating developers should prepare long‑term safety...
Virology breakthroughs: single‑shot HIV neutralization and continuous norovirus culture
Wistar Institute scientists reported a single‑shot HIV vaccine candidate that elicited neutralizing antibodies in nonhuman primates, marking a notable preclinical advance published in Nature...
Scaling spatial and computational genomics: PharosAI teams with 10x; Nature Biotech debuts PlasMAAG
PharosAI announced a multi‑institution consortium to build multimodal cancer datasets on 10x Genomics' Xenium spatial platform, backed by £18.9 million from UK government Research Ventures...
Platform funding and market moves: CIRM backs scalable gene therapy; PrimeGen pursues SPAC
The California Institute for Regenerative Medicine approved a $100 million RAPID initiative to accelerate platform-based in vivo genetic therapies for rare diseases, pushing toward scalable...
AI‑native lab tools: Phylo raises $13.5M to commercialize Biomni Lab
Phylo, a Stanford spinout, closed a $13.5 million seed round led by Andreessen Horowitz and Menlo Ventures to launch Biomni Lab, an AI‑enabled integrated biology environment that automates...
BARDA launches $100M antiviral prize: first stage open
The U.S. Biomedical Advanced Research and Development Authority (BARDA) launched a $100 million prize competition to accelerate small‑molecule antivirals targeting Togaviridae and Flaviviridae....
Medicare to cover FDA‑approved MCEDs: reimbursement path cleared
Congress approved an appropriations bill that makes FDA‑cleared multi‑cancer early detection (MCED) tests eligible for Medicare coverage beginning in 2029. The provision ties reimbursement to FDA...
CIRM commits $100M to platform gene‑therapy approaches for rare diseases
The California Institute for Regenerative Medicine (CIRM) approved a $100 million initiative — the RAPID program — to fund platform approaches for in‑vivo genetic therapies across rare diseases....
Illumina to sequence San Diego Zoo Frozen Zoo: conservation genomics push
Illumina announced a partnership with the San Diego Zoo Wildlife Alliance to sequence up to 4,000 archived samples from the Frozen Zoo biobank, covering roughly 1,300 species. Illumina will...
Phylo nets $13.5M seed to build AI‑native lab workspace
Phylo closed a $13.5 million seed round co‑led by Andreessen Horowitz and Menlo Ventures’ Anthology Fund to commercialize Biomni Lab, an AI‑enabled integrated environment for biological research....
Veradermics prices $256M IPO to fund pivotal hair‑loss trials
Veradermics priced a $256.3 million initial public offering to advance VDPHL‑01, an oral formulation of minoxidil designed to avoid cardiovascular risks of systemic dosing. The proceeds will...